Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutant Non-small Cell Lung Cancer”

205 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 205 results

Not applicableLooking for participantsNCT07143045
What this trial is testing

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Who this might be right for
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd. 800
Not applicableLooking for participantsNCT05997719
What this trial is testing

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 150
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Testing effectiveness (Phase 2)Study completedNCT03256136
What this trial is testing

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644
What this trial is testing

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 44
Testing effectiveness (Phase 2)Study completedNCT04147351
What this trial is testing

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Who this might be right for
NSCLC Stage IIIB~IV
National Taiwan University Hospital 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Looking for participantsNCT06355609
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03433469
What this trial is testing

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Who this might be right for
Stage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung Cancer+4 more
University of California, San Francisco 27
Not applicableUnknownNCT04778800
What this trial is testing

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Who this might be right for
NSCLCBrain MetastasesLeptomeningeal Metastasis
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)UnknownNCT06334757
What this trial is testing

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Henan Cancer Hospital 46
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Early research (Phase 1)Study completedNCT02520778
What this trial is testing

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7+3 more
National Cancer Institute (NCI) 27
Testing effectiveness (Phase 2)Study completedNCT02321540
What this trial is testing

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)Looking for participantsNCT05011487
What this trial is testing

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Looking for participantsNCT05536505
What this trial is testing

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Who this might be right for
MRD
Guangdong Association of Clinical Trials 180
Load More Results